Krystal Biotech (NASDAQ:KRYS) had its price objective raised by HC Wainwright from $32.00 to $35.50 in a report published on Monday, The Fly reports. They currently have a buy rating on the stock.
Several other equities research analysts have also issued reports on KRYS. Zacks Investment Research upgraded Krystal Biotech from a hold rating to a buy rating and set a $18.00 price target for the company in a report on Tuesday, October 9th. LADENBURG THALM/SH SH set a $38.00 price target on Krystal Biotech and gave the company a buy rating in a report on Thursday, July 19th. Chardan Capital began coverage on Krystal Biotech in a report on Thursday, June 28th. They set a buy rating and a $35.00 price target for the company. William Blair began coverage on Krystal Biotech in a report on Tuesday, July 10th. They set an outperform rating for the company. Finally, ValuEngine upgraded Krystal Biotech from a hold rating to a buy rating in a report on Friday, September 21st. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The company currently has an average rating of Buy and an average target price of $32.30.
Shares of Krystal Biotech stock opened at $22.25 on Monday. The stock has a market cap of $235.06 million and a PE ratio of -13.96. Krystal Biotech has a 52-week low of $8.03 and a 52-week high of $24.89.
Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, August 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.12. Sell-side analysts anticipate that Krystal Biotech will post -1.01 earnings per share for the current year.
A hedge fund recently raised its stake in Krystal Biotech stock. BlackRock Inc. increased its stake in Krystal Biotech Inc (NASDAQ:KRYS) by 75.4% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 13,040 shares of the company’s stock after purchasing an additional 5,607 shares during the quarter. BlackRock Inc. owned approximately 0.13% of Krystal Biotech worth $194,000 at the end of the most recent reporting period. 21.77% of the stock is owned by institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Recommended Story: 52-Week High/Low
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.